Investments (Tables)

12 Months Ended

Jun. 30, 2024

Equity Method Investments and Joint Ventures [Abstract]

Equity investments by measurement category as of June 30, 2024 and June 30, 2023 were as follows (in thousands):


Measurement category	2024		2023
Fair value	$	12,026	$	12,423
Measurement alternative	73,739		68,748
Equity method	65,462		65,366
Total	$	151,227	$	146,537

Schedule of Changes in Equity Investments

The following table shows a reconciliation of the changes in our equity investments for the year ended June 30, 2024 (in thousands):


	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	68,748	$	12,423	$	65,366	$	146,537
Additions to investments	8,640		1,000		3,125		12,765
Observable price adjustments on non-marketable equity securities	2,315		—		—		2,315
Impairment of investments	(4,963)		—		—		(4,963)

Proceeds from exits of investments	(1,000)		—		—		(1,000)
Unrealized losses on marketable equity securities	—		(1,397)		—		(1,397)
Loss attributable to equity method investments	—		—		(1,848)		(1,848)

Foreign currency translation adjustments	(1)		—		(1,181)		(1,182)
Carrying value at the end of the period	$	73,739	$	12,026	$	65,462	$	151,227

The following table shows a reconciliation of the changes in our equity investments for the year ended June 30, 2023 (in thousands):


	Non-marketable securities		Marketable securities		Equity method investments		Total
Balance at the beginning of the period	$	39,290	$	9,167	$	9,918	$	58,375
Additions to investments (1)	21,738		4,991		62,733		89,462
Observable price adjustments on non-marketable equity securities	12,612		—		—		12,612
Impairment of investments	(4,892)		—		—		(4,892)
Realized gains on marketable and non-marketable equity securities	3,937		—		—		3,937
Proceeds from exits of investments	(3,937)		—		—		(3,937)
Unrealized losses on marketable equity securities	—		(1,735)		—		(1,735)
Loss attributable to equity method investments	—		—		(7,265)		(7,265)
Dividends received	—		—		(2,873)		(2,873)
Foreign currency translation adjustments	—		—		2,853		2,853
Carrying value at the end of the period	$	68,748	$	12,423	$	65,366	$	146,537

(1)Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.